Imidazo(5,1-F)(1,2,4)triazine, 4-(3-(fluoro-18F)-1-azetidinyl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)- | 1438434-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Imidazo(5,1-F)(1,2,4)triazine, 4-(3-(fluoro-18F)-1-azetidinyl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-
• 英文别名: 4-(3-(18F)fluoranylazetidin-1-yl)-7-methyl-5-[1-methyl-5-[4-(trifluoromethyl)phenyl]pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazine
• CAS: 1438434-94-6
• 化学式: C₂₀H₁₇F₄N₇
• 分子量: 430.397
• InChiKey: NXNPDXUSIAPGFQ-GJQNQZCXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.1
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1-(7-methyl-5-{1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}imidazo[5,1-f][1,2,4]triazin-4-yl)azetidin-3-ol 在 [18F]-tetrabutylammonium fluoride 、 三乙胺 作用下， 以 2-甲基-2-丁醇 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 Imidazo(5,1-F)(1,2,4)triazine, 4-(3-(fluoro-18F)-1-azetidinyl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-
  参考文献：
  名称：

  Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand

  摘要：

  To accelerate the discovery of novel small molecule central nervous system (CNS) positron emission tomography (PET) ligands, we aimed to define a property space that would facilitate ligand design and prioritization, thereby providing a higher probability of success for novel PET ligand development. Toward this end, we built a database consisting of 62 PET ligands that have successfully reached the clinic and IS radioligands that failed in late-stage development as negative controls. A systematic analysis of these ligands identified a set of preferred parameters for physicochemical properties, brain permeability, and nonspecific binding (NSB). These preferred parameters have subsequently been applied to several programs and have led to the successful development of novel PET ligands with reduced resources and timelines. This strategy is illustrated here by the discovery of the novel phosphodiesterase 2A (PDE2A) PET ligand 4-(3-[F-18]fluoroazetidin-1-yl)-7methyl-5-{1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}imidazo[5,1-f][1,2,4]triazine, [F-18]PF-05270430 (5).

  DOI：

  10.1021/jm400312y

文献信息

• 氟代二硫代磷酸酯类化合物及其制备方法与 应用
  申请人：厦门大学

  公开号：CN110483603B

  公开（公告）日：2021-03-26

  本发明涉及氟代二硫代磷酸酯类化合物及其制备方法与应用，所述氟代二硫代磷酸酯类化合物具有式(I)所示结构。本发明首次以1,3,2‑二硫磷杂环戊烷为18/19F标记前体，通过亲核取代‑消去的低反应能垒标记策略来超快速、一步构建氟代二硫代磷酸酯类化合物；本发明的氟代二硫代磷酸酯类化合物可以在含水溶液中制备，同时标记条件温和，反应时间短，在20℃的条件下反应30秒即可达到97％的产率，无需干燥F‑，比活度高、纯化方便，标记产物体内外稳定性好，在制备磷酸类似物分子探针、热敏感和溶剂敏感的多肽或蛋白质等生物分子的正电子药物领域具有广阔的应用前景。
• J. Med. Chem. 2013, 56, 4568-4579
  作者：

  DOI：——

  日期：——